BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 27807822)

  • 1. Vortioxetine: A Review in Cognitive Dysfunction in Depression.
    Frampton JE
    Drugs; 2016 Nov; 76(17):1675-1682. PubMed ID: 27807822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
    Baune BT; Sluth LB; Olsen CK
    J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vortioxetine for the treatment of major depressive disorder.
    Tritschler L; Felice D; Colle R; Guilloux JP; Corruble E; Gardier AM; David DJ
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):731-45. PubMed ID: 25166025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.
    Mahableshwarkar AR; Zajecka J; Jacobson W; Chen Y; Keefe RS
    Neuropsychopharmacology; 2015 Jul; 40(8):2025-37. PubMed ID: 25687662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults.
    McIntyre RS; Lophaven S; Olsen CK
    Int J Neuropsychopharmacol; 2014 Oct; 17(10):1557-67. PubMed ID: 24787143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VORTIOXETINE - THE NEW ANTIDEPRESSANT AGENT WITH PROCOGNITIVE PROPERTIES.
    Dziwota E; Olajossy M
    Acta Pol Pharm; 2016 Nov; 73(6):1433-1437. PubMed ID: 29634095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vortioxetine for the treatment of major depression.
    Dhir A
    Drugs Today (Barc); 2013 Dec; 49(12):781-90. PubMed ID: 24524096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls.
    Smith J; Browning M; Conen S; Smallman R; Buchbjerg J; Larsen KG; Olsen CK; Christensen SR; Dawson GR; Deakin JF; Hawkins P; Morris R; Goodwin G; Harmer CJ
    Mol Psychiatry; 2018 May; 23(5):1127-1133. PubMed ID: 28533517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram.
    Vieta E; Sluth LB; Olsen CK
    J Affect Disord; 2018 Feb; 227():803-809. PubMed ID: 29673132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine.
    Orsolini L; Tomasetti C; Valchera A; Iasevoli F; Buonaguro EF; Fornaro M; Fiengo ALC; Martinotti G; Vellante F; Matarazzo I; Vecchiotti R; Perna G; Di Nicola M; Carano A; Di Bartolomeis A; De Giannantonio M; De Berardis D
    CNS Neurol Disord Drug Targets; 2017; 16(1):65-92. PubMed ID: 27781949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder.
    Al-Sukhni M; Maruschak NA; McIntyre RS
    Expert Opin Drug Saf; 2015 Aug; 14(8):1291-304. PubMed ID: 26022537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vortioxetine for the treatment of depression.
    Pearce EF; Murphy JA
    Ann Pharmacother; 2014 Jun; 48(6):758-65. PubMed ID: 24676550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vortioxetine: a review of its use in major depressive disorder.
    Garnock-Jones KP
    CNS Drugs; 2014 Sep; 28(9):855-74. PubMed ID: 25145538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder.
    McIntyre RS; Florea I; Tonnoir B; Loft H; Lam RW; Christensen MC
    J Clin Psychiatry; 2017 Jan; 78(1):115-121. PubMed ID: 27780334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data.
    Sanchez C; Asin KE; Artigas F
    Pharmacol Ther; 2015 Jan; 145():43-57. PubMed ID: 25016186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Vortioxetine in the treatment of major depression].
    de Bartolomeis A; Fagiolini A; Maina G
    Riv Psichiatr; 2016; 51(6):215-230. PubMed ID: 27996982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vortioxetine: a New Treatment for Major Depressive Disorder.
    Connolly KR; Thase ME
    Expert Opin Pharmacother; 2016; 17(3):421-31. PubMed ID: 26679430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacological properties of vortioxetine and its pre-clinical consequences].
    David DJ; Tritschler L; Guilloux JP; Gardier AM; Sanchez C; Gaillard R
    Encephale; 2016 Feb; 42(1 Suppl 1):1S12-23. PubMed ID: 26879252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant.
    Sowa-Kućma M; Pańczyszyn-Trzewik P; Misztak P; Jaeschke RR; Sendek K; Styczeń K; Datka W; Koperny M
    Pharmacol Rep; 2017 Aug; 69(4):595-601. PubMed ID: 28499187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Vortioxetine: a new antidepressant to treat depressive episodes].
    Colle R; Corruble E
    Encephale; 2016 Feb; 42(1):48-58. PubMed ID: 26358483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.